Resistance to targeted therapy in renal-cell carcinoma - Abstract - UroToday PDF Print
UroToday... mammalian target of rapamycin (mtor), has produced robust clinical effects and revolutionised the treatment of metastatic renal-cell carcinoma (RCC).

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.